LONZA N/ CH0013841017 /
2024-09-02 2:42:20 PM | Chg. -5.80 | Volume | Bid2:42:25 PM | Ask2:42:25 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
549.80CHF | -1.04% | 38,198 Turnover: 21.01 mill. |
549.60Bid Size: 258 | 550.00Ask Size: 218 | 40.99 bill.CHF | 0.73% | 61.98 |
GlobeNewswire
08-08
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-06
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
06-14
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire
05-30
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire
05-15
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire
05-08
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
04-04
Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire
04-04
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...
GlobeNewswire
02-27
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
01-04
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
GlobeNewswire
2023-12-19
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...
GlobeNewswire
2023-12-09
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...
GlobeNewswire
2023-12-07
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...
GlobeNewswire
2023-11-06
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
2023-10-16
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...
GlobeNewswire
2023-10-02
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
GlobeNewswire
2023-09-20
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023